AngioDynamics, Inc.
- Open
- 13.46
- Day high
- 13.81
- Day low
- 13.43
- Prev close
- 13.71
- Volume
- 141K
- Mkt cap
- $571M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 3.3
- P/S
- 1.8
- Yield
- —
- Per share
- —
AngioDynamics, Inc. (ANGO) is a Healthcare company listed on NASDAQ. The stock is up 52% over the past year.
AngioDynamics, Inc. (ANGO) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ANGO earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 14, 2026 | $-0.11 | $-0.07 | +36.4% | $87M | +7.9% |
| Apr 2, 2026 | $-0.11 | $-0.07 | +36.4% | $78M | +2.2% |
| Jan 6, 2026 | $-0.10 | $-0.15 | -53.4% | $79M | +4.3% |
| Oct 2, 2025 | $-0.14 | $-0.10 | +28.6% | $76M | -0.8% |
| Jul 15, 2025 | $-0.13 | $-0.03 | +76.9% | $80M | +7.9% |
| Apr 2, 2025 | $-0.13 | $0.03 | +123.1% | $72M | -3.0% |
| Jan 8, 2025 | $-0.11 | $-0.04 | +63.6% | $73M | +3.2% |
| Oct 3, 2024 | $-0.15 | $-0.11 | +26.7% | $67M | -0.6% |
| Jul 16, 2024 | $-0.20 | $-0.06 | +70.0% | $71M | +0.2% |
| Apr 4, 2024 | $-0.14 | $-0.16 | -14.3% | $75M | -0.7% |
| Jan 5, 2024 | $-0.09 | $-0.05 | +44.4% | $79M | -3.6% |
| Oct 4, 2023 | $-0.14 | $-0.12 | +14.3% | $79M | +1.3% |
ANGO insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Oct 22, 2025 | Weiss Lawrence Tofficer: SVP, Chief Legal Officer | Buy | 10,000 | $11.81 |
| Oct 14, 2025 | Trowbridge Stephen Aofficer: EVP and CFO | Buy | 890 | $11.16 |
| Oct 9, 2025 | Clemmer James Cdirector, officer: President and CEO | Buy | 10,000 | $11.15 |
| Jul 22, 2025 | Clemmer James Cdirector, officer: President and CEO | Tax | 344 | $8.69 |
| Jul 22, 2025 | Campbell Chad Thomasofficer: SVP/GM, Vascular Access | Tax | 359 | $8.69 |
| Jul 22, 2025 | Nighan Warren JRofficer: SVP Quality and Regulatory | Tax | 277 | $8.99 |
| Jul 22, 2025 | Nighan Warren JRofficer: SVP Quality and Regulatory | Tax | 251 | $8.69 |
| Jul 22, 2025 | Piccinini Lauraofficer: SVP International | Tax | 616 | $8.69 |
| Jul 22, 2025 | Trowbridge Stephen Aofficer: EVP and CFO | Tax | 667 | $8.99 |
| Jul 22, 2025 | Campbell Chad Thomasofficer: SVP/GM, Vascular Access | Tax | 395 | $8.99 |
| Jul 22, 2025 | Trowbridge Stephen Aofficer: EVP and CFO | Tax | 2,585 | $8.69 |
| Jul 22, 2025 | Nighan Warren JRofficer: SVP Quality and Regulatory | Tax | 735 | $8.69 |
| Jul 22, 2025 | Campbell Chad Thomasofficer: SVP/GM, Vascular Access | Tax | 1,025 | $8.69 |
| Jul 22, 2025 | Clemmer James Cdirector, officer: President and CEO | Tax | 8,307 | $8.69 |
| Jul 22, 2025 | Clemmer James Cdirector, officer: President and CEO | Tax | 3,673 | $8.99 |
Source: ANGO SEC Form 4 filings, latest Oct 22, 2025. For informational purposes only — not investment advice.
See the full ANGO insider & 13F page →AngioDynamics, Inc. company profile
Overview
AngioDynamics, Inc. (NASDAQ:ANGO) is a medical device company founded in 1988 and headquartered in Latham, New York. The company designs, manufactures, and sells specialized medical devices used by healthcare professionals for treating peripheral vascular disease, providing vascular access, and performing oncology and surgical procedures. Since going public in 2004, AngioDynamics has been transforming from a traditional medical device manufacturer into a focused medical technology company, concentrating on high-growth therapeutic areas including minimally invasive cancer treatment and advanced vascular interventions.
Business
AngioDynamics operates in the medical device industry, specifically focusing on interventional medicine and minimally invasive therapeutic procedures. The company's business is organized into two primary segments that serve different but complementary markets in healthcare. The MedTech segment represents approximately 44% of total revenue and focuses on advanced therapeutic devices for treating serious medical conditions. This segment includes three key platforms: Auryon is an atherectomy system that uses laser technology to remove plaque buildup from blood vessels, particularly effective in treating peripheral artery disease in patients with diabetes or other complex conditions. NanoKnife is an irreversible electroporation system that uses electrical pulses to destroy cancer cells while preserving surrounding healthy tissue, currently used for treating pancreatic, liver, and other soft tissue cancers. The Mechanical Thrombectomy portfolio includes AngioVac and AlphaVac systems, which are large-bore aspiration devices designed to remove blood clots from major vessels, treating conditions like pulmonary embolism and deep vein thrombosis. The Med Device segment comprises approximately 56% of revenue and focuses on essential vascular access products used in hospitals and outpatient settings. This includes peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters that enable healthcare providers to deliver medications, chemotherapy, antibiotics, and other treatments directly into patients' central venous system. These products are sold under various brand names including BioFlo, Xcela, SmartPort, and DuraMax, and represent the company's traditional core business serving critical care, oncology, and dialysis patients.
Revenue model
AngioDynamics generates revenue primarily through direct product sales to healthcare institutions and through distributor relationships. The company sells its devices to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional oncologists, surgical oncologists, and critical care nurses across hospitals, outpatient surgery centers, and office-based laboratories. The business model varies by product category. For capital equipment like NanoKnife systems and Auryon devices, the company generates initial capital sales revenue followed by recurring disposable sales as procedures are performed. The mechanical thrombectomy devices and vascular access products generate revenue through direct device sales per procedure or patient treatment. The MedTech segment typically commands higher gross margins (65-68%) due to the specialized nature and clinical value of these advanced therapeutic devices, while the Med Device segment operates at lower but stable margins reflecting the more commoditized nature of vascular access products. Several factors influence the company's profitability and growth trajectory. Positive drivers include the aging population requiring more vascular interventions, increasing adoption of minimally invasive procedures over traditional surgery, expanding clinical indications for existing products, and successful reimbursement approvals that make procedures more accessible to patients. The company benefits from procedural volume growth as hospitals resume elective procedures and invest in advanced technologies. Conversely, margin pressure can result from healthcare cost containment efforts, competitive pricing dynamics, supply chain inflation affecting manufacturing costs, and regulatory delays that postpone new product launches or indication expansions. Hospital staffing shortages and procedural delays can also impact device utilization rates and revenue growth.
Competitive moat
AngioDynamics possesses a moderate competitive moat built primarily around specialized clinical expertise, established relationships with interventional specialists, and regulatory barriers to entry. The company's strongest defensive position lies in its NanoKnife technology, which represents a unique approach to cancer treatment through irreversible electroporation - a differentiated mechanism compared to traditional thermal ablation methods. This technology platform has significant regulatory moats, requiring extensive clinical trials and FDA approvals for each new indication, creating barriers for potential competitors. The company's relationships with interventional radiologists and specialized physicians provide some customer stickiness, particularly as these practitioners develop expertise with specific devices and integrate them into their clinical workflows. AngioDynamics has built clinical evidence and training programs around its key platforms, creating switching costs for healthcare providers who have invested in learning these technologies. However, the company's moat faces meaningful challenges. The medical device industry is highly competitive with well-funded competitors including Boston Scientific, Medtronic, and other large medical technology companies that possess greater resources for research and development, clinical trials, and market penetration. In the atherectomy market, Auryon competes against established players with broader product portfolios and stronger hospital relationships. The vascular access business, while stable, operates in a relatively commoditized market with limited differentiation opportunities. Additionally, the company's smaller scale compared to industry giants limits its ability to invest heavily in breakthrough innovations or acquire complementary technologies, potentially constraining its long-term competitive position.
Risks & safety
AngioDynamics demonstrates a reasonable margin of safety from a balance sheet perspective, though operational cash flow remains inconsistent. • Liquidity and Debt: Strong cash position of $44.8 million with zero debt, providing substantial financial flexibility. Current ratio of 2.21 indicates solid short-term liquidity coverage. • Cash Flow: Recent quarters show volatile operating cash flows, with Q3 2025 generating negative $13.2 million in operating cash flow and negative $15.0 million in free cash flow, indicating ongoing cash consumption for operations and investments. • Valuation Metrics: Trading at 2.04x book value and negative EBITDA multiples due to current losses. Graham net-net ratio of 0.33 suggests the stock trades below tangible book value, potentially offering some downside protection. • Profitability Path: Company targeting positive adjusted EBITDA and expects to achieve full-year profitability by fiscal 2027 through manufacturing restructuring and revenue growth in higher-margin MedTech products. • Other Considerations: Revenue growth trajectory remains positive with MedTech segment showing strong 22% growth, but overall profitability timeline extends several years into the future, creating execution risk.
Recent development
Over the past few years, AngioDynamics has undergone a significant strategic transformation focused on becoming a pure-play medical technology company. The company divested non-core businesses including its Dialysis and BioSentry product lines to Merit Medical, allowing management to concentrate resources on high-growth MedTech platforms. This portfolio rationalization helped strengthen the balance sheet and eliminated debt, positioning the company in a net cash position. The company has made substantial investments in clinical development to expand the addressable markets for its key products. Most notably, AngioDynamics completed enrollment in the PRESERVE clinical trial for NanoKnife's prostate cancer indication, with FDA approval expected by the end of 2024. This represents a potential $700 million market opportunity that could significantly expand NanoKnife's commercial potential beyond its current pancreatic and liver cancer applications. Additionally, the company received FDA breakthrough device designation for AngioVac in treating right heart vegetation, accelerating the regulatory pathway for this important indication. Manufacturing restructuring represents another major strategic initiative, with AngioDynamics transitioning from internal manufacturing to a fully outsourced model. This two-year transformation is expected to generate $15 million in annualized cost savings by fiscal 2027 and provide a clearer pathway to profitability. The company has also pursued international expansion, obtaining CE Mark approval for Auryon to enter European markets and planning similar approvals for other products. Recent commercial developments include launching the AlphaVac device for pulmonary embolism treatment and preparing for the AMBITION BTK clinical trial to demonstrate Auryon's effectiveness in below-the-knee vascular interventions.
ANGO company profile · for informational purposes only — not investment advice.
Track ANGO with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free